UF startup Breathtec Biomedical Inc. is pleased to provide details on Nash Pharmaceutical’s plans for the next 12 month period. Breathtec recently announced that it has signed a letter of intent to acquire 100 percent of the shares of Nash Pharma. Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis, chronic kidney disease and inflammatory bowel disease.
Through its ongoing research programs, Nash Pharma has developed data that supports the advancement of up to 7 drug candidates into Phase II studies, with a number of the candidates outperforming current standard of care therapies when tested in animal models.
“The addition of Nash Pharma’s technology and its focus on CKD and NASH is complimentary to Breathtec’s ongoing program to develop a device for early screening for the same disease states,” says Christopher J. Moreau, CEO of Breathtec Biomedical Inc. “We look forward to advancing our knowledge about these diseases and to leverage our expertise to help find markers in the breath that can help screen for these diseases.”
Learn more about Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year.